[ad_1]
A step forward in the struggle against AIDS . In a new study published in Lancet an international team claims to have obtained very promising results for an anti-HIV vaccine mosaic that should confer protection against different viral strains. 19659003] From tests in humans, the vaccine seems to be well tolerated and secure and cause an immune system response. Parallel experimentation in rhesus monkeys also gave animals protection against hiv-like virus in 67% cases. Fundamental prerequisites, which pave the way for trials to prove the effectiveness of the vaccine in preventing HIV infection even in humans
AIDS Today
Can – do you not hear it more as it was, but Aids has not disappeared: it is estimated that today 37 million of people are affected and every year there are million new infections (1.8 million new cases in 2016). There is currently no cure for AIDS, but advances in treatment allow for near-normal living, and most importantly, if therapy is diligently followed, they prevent HIV-positive people from spreading the infection.
prevention of the contagion, the news is late. Beyond the use of condoms and pre-exposure prophylaxis for people at risk (which is effective but only if taken daily), new preventive strategies recorded few of success with sufficient relative existence: there are many different strains of HIV and the virus has the ability to change quickly – problems that have so far nullified the scientists' attempts to prevent the virus. infection.
A vaccine "mosaic" ]
An effective vaccine, in short, is not there yet. But something could change in the near future: in a randomized, double-blind placebo-controlled study, a large team of scientists tested some mosaic vaccines or by combining parts of different viral strains in order to provide almost universal protection .
Medical devices were tested on 392 persons in good health between the ages of 18 and 50 and recruited from the United States, Rwanda, Uganda, South Africa and Thailand . Treatment consisted of 4 administrations of vaccine on 48 weeks .
The vaccines tested proved well tolerated and safe and induced an anti-hiv response to the immune system. A particular combination, then, showed a significant efficacy in parallel experimentation that the researchers conducted on 72 rhesus monkeys : the protected vaccine 67% [19459003d]
These results represent an important step forward in the development of an HIV vaccine, but, as pointed out Dan Barouch Professor of Medicine at Harvard Medical School and lead author of the study, "you have to be careful and it is clear that there is still a lot of work to be done before an effective HIV vaccine is available." The result of these initial tests, in fact, should be interpreted as a fundamental premise of baduming the effectiveness of the vaccine in humans, but the presence of an immune response does not constitute a sufficient evidence . ] "The challenges in developing an HIV vaccine are unprecedented and the ability to induce specific immune responses against HIV does not necessarily mean that a vaccine will protect humans from the infection." ", added Barouch.
the results obtained are auspicious and will allow researchers to test the effectiveness of the vaccine on 2600 women at risk in southern Africa.
Via: Wired.it
] <! – ->
<! –
Source link
